Neuropathic pain affects more than 20 million people in the U.S., and at least a quarter of these cases are puzzling for ...

Neuropathic pain is a chronic and debilitating condition that impacts around 10% of the population in both the United States and Europe. Despite advances in understanding the mechanisms of neuropathic ...

European researchers have mapped the most comprehensive phenotyping of neuropathic ... pain and identified genetic markers associated with this serious condition. Long-term, low-dose antiviral ...

European researchers have mapped the most comprehensive phenotyping of neuropathic ... pain. People with a genetic variant in opioid receptors may need higher doses of painkillers for the ...

Cannabidiol (CBD) holds great promise as a treatment ... pain, there’s a chance it may work for nerve pain. Neuropathy, or nerve dysfunction, doesn’t always result in nerve pain, or ...

Nerve Fresh is a nerve support supplement developed to help reduce neuropathic pain and promote a healthy ... the facility follows all the guidelines issued by the FDA. The supplement is non ...

A recent study has raised concerns about the widespread prescription of antidepressants for chronic pain, warning that many ...

achieves 60% greater efficacy than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain. These results build on earlier successes across various pain models ...

(NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, announces compelling new preclinical findings showing that Ketamir-2, a novel oral ketamine analog, achieves 60% greater ...

MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant ...

The new preclinical data show that Ketamir-2 is 60% more effective than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain. The study used the paclitaxel ...